Tian Zhang, MD

Assistant Professor of Medicine

Member of the Duke Cancer Institute

Campus mail DUMC 103861, Durham, NC 27710

Phone (919) 668-4667

Email address tian.zhang2@duke.edu

Education and Training

Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
M.D., Harvard Medical School, 2009

Grants

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)
Merrimack MM-310-01-01-01
An Open-Label Study of Rovalpituzumab
A first in human study of repeat dosing with REGN2810 a fully human antibody to programmed death - 1 (PD-1) as single therapy and in combination with selected
Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
CTC-Immune Checkpoints
A Phase I/II open label multicenter study of the safety and efficacy of LAG525 single agent in combination with PDR001 adminitered to patients
A Retrospective Study to Evaluate the Clinical Effectiveness of the OmniSeq Immune Advance Test to Predict Response to Checkpoint Inhibitors
A study is to develop a retrospective database to study the PGDx TMB +MSI assay associated with clinical responses to immune checkpoint inhibitors (CPIs)
A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer
Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer

Publications

Labriola, MK, Batich, KA, Zhu, J, McNamara, MA, Harrison, MR, Armstrong, AJ, George, DJ, and Zhang, T. "Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma." Clinical Genitourinary Cancer (February 5, 2019). (Review)

PMID

30858035

Full Text

Zhang, T, George, DJ, and Armstrong, AJ. "Precision Medicine Approaches When Prostate Cancer Akts Up." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 25, no. 3 (February 2019): 901-903.

PMID

30206162

Full Text

Conroy, JM, Pabla, S, Nesline, MK, Glenn, ST, Papanicolau-Sengos, A, Burgher, B, Andreas, J, Giamo, V, Wang, Y, Lenzo, FL, Bshara, W, Khalil, M, Dy, GK, Madden, KG, Shirai, K, Dragnev, K, Tafe, LJ, Zhu, J, Labriola, M, Marin, D, McCall, SJ, Clarke, J, George, DJ, Zhang, T, Zibelman, M, Ghatalia, P, Araujo-Fernandez, I, de la Cruz-Merino, L, Singavi, A, George, B, MacKinnon, AC, Thompson, J, Singh, R, Jacob, R, Kasuganti, D, Shah, N, Day, R, Galluzzi, L, Gardner, M, and Morrison, C. "Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors." Journal for Immunotherapy of Cancer 7, no. 1 (January 24, 2019): 18-null.

PMID

30678715

Full Text

Zhang, T, Armstrong, AJ, George, DJ, and Huang, J. "The promise of immunotherapy in genitourinary malignancies." Precision Clinical Medicine 1, no. 3 (December 19, 2018): 97-101.

PMID

30687563

Full Text

Koontz, BF, Hoffman, KE, Healy, P, George, DJ, Harrison, MR, Zhang, T, Lee, WR, Berry, WR, Pugh, TJ, Bratt, L, Hobbs, B, Halabi, S, Corn, PG, Armstrong, A, Shobe, K, Tojong, B, Thornburg, B, Brummer, K, and Allen, D. "Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer.": Elsevier BV, November 2018.

Full Text

Bakthavatsalam, S, Sleeper, ML, Dharani, A, George, DJ, Zhang, T, and Franz, KJ. "Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells." Angewandte Chemie (International Ed. in English) 57, no. 39 (September 2018): 12780-12784.

PMID

30025197

Full Text

Ware, KE, Gupta, S, Eng, J, Foo, W-C, Crawford, L, Austin, G, Puviindran, B, Freedman, J, Patierno, SR, Zhang, T, Corcoran, D, Pierobon, M, Petricoin, E, Somarelli, JA, and Armstong, AJ. "Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer.": American Association for Cancer Research (AACR), August 15, 2018.

Full Text

George, DJ, Heath, EI, Sartor, AO, Sonpavde, G, Berry, WR, Healy, P, Winters, C, Riggan, C, Anand, M, Kephart, J, Milowsky, MI, Fleming, MT, Balaji, KC, Zhang, T, Bitting, RL, Harrison, MR, McNamara, MA, Freedman, JA, Halabi, S, Armstrong, AJ, and Bruner, D. "Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP)." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL. June 1, 2018 - June 5, 2018.: AMER SOC CLINICAL ONCOLOGY, June 20, 2018.

Scholars@Duke

Myung, JH, Eblan, MJ, Caster, JM, Park, S-J, Poellmann, MJ, Wang, K, Tam, KA, Miller, SM, Shen, C, Chen, RC, Zhang, T, Tepper, JE, Chera, BS, Wang, AZ, and Hong, S. "Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research 24, no. 11 (June 2018): 2539-2547.

PMID

29545463

Full Text

Labriola, M, Foo, W-C, George, DJ, and Zhang, T. "Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report." Clinical Genitourinary Cancer 16, no. 3 (June 2018): e509-e512.

PMID

29636282

Full Text

Tian Zhang, MD

Education and Training

Grants

Publications

Pages